Journals / Molecular Imaging and Radionuclide Therapy / 2014 / Cilt: 23 - Sayı: 2

Multipl Skleroz Hastalarında Interferon-Beta1a Tedavisinin Tiroid ve Tükrük Bezi Fonksiyonları Üzerindeki Etkisinin Kantitatif Tükrük Bezi Sintigrafisi ile Değerlendirilmesi

Assessment of the Effect of Interferon-Beta1a Therapy on Thyroid and Salivary Gland Functions in Patients with Multiple Sclerosis Using Quantitative Salivary Gland Scintigraphyz

Pages
43–47
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thyroid and salivary gland functions were also found to remain unchanged in untreated MS patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Interferon-beta (IFN-β) is widely used in patients with multiple sclerosis (MS), a demyelinating disease of the central nervous system.
📊
Key Findings & Data:High incidence of thyroid dysfunction has been reported after administration of IFN-β in MS patients.
💡
Conclusion & Impact:Thyroid and salivary gland functions were also found to remain unchanged in untreated MS patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Interferon-beta (IFN-β) is widely used in patients with multiple sclerosis (MS), a demyelinating disease of the central nervous system. High incidence of thyroid dysfunction has been reported after administration of IFN-β in MS patients. The aim of this study was to assess the effect of IFN-β1a therapy on simultaneous thyroid and salivary gland function in patients with MS using quantitative salivary gland scintigraphy (QSGS). Methods: Fifteen relapsing-remitting (RR) MS patients treated with IFN-β1a and two control groups consisting of 15 untreated RRMS patients and 20 healthy age and sex-matched individuals were included in the study. The functional status of the salivary and thyroid glands was analysed with the QSGS and laboratory tests, including thyroid function and thyroid antibody. After intravenous administration of 150 MBq Tc-99m pertechnetate, dynamic study was performed for 25 minutes. Salivary gland secretion was stimulated with oral lemon juice at 15 minutes. At the end of dynamic study, a static image in the same projection was taken. Uptake ratios at 12-14 min (UR%) and stimulated excretion fraction (EF%) of each parotid and submandibular gland were calculated automatically from SGS. Thyroid uptake ratio (TUR) of thyroid gland was calculated from the static image. Results: All MS patients treated and untreated with IFN-β1a, and healthy individuals were euthyroid. Anti-thyroid peroxidase antibody (anti-TPO) was detected in 4 out of 15 MS patients (26.6%) treated with IFN-β1a. There was no significant differences in the UR, EF and TUR values among MS patients treated and untreated with IFN-β1a, and healthy controls (p>0.05). Although the TUR values in MS patients treated with IFN-β1a were less than those of the both control group, the difference was not statistically significant (p>0.05). Conclusion: IFN-β1a therapy was demonstrated to have no effect on thyroid and salivary gland functions using QSGS in patients with MS. Thyroid and salivary gland functions were also found to remain unchanged in untreated MS patients.

Özet

Amaç: Santral sinir sisteminin demiyelinizan bir hastalığı olan multipl skleroz (MS) hastalarında interferon-beta (IFN-β) yaygın olarak kullanılır. MS hastalarında IFN-β verilmesinden sonra yüksek oranda tiroid fonksiyon bozukluğu bildirilmiştir. Bu çalışmanın amacı, MS hastalarında IFN-β1a tedavisinin tiroid ve tükrük bezi fonksiyonları üzerindeki etkisinin eşzamanlı olarak kantitatif tükrük bezi sintigrafisi (KTBS) ile değerlendirilmesidir. Yöntem: IFN-β1a ile tedavi edilen 15 relapsing-remitting (RR) MS hastası ve tedavi edilmemiş 15 RRMS hastası ile yaş, cinsiyet uyumlu 20 sağlıklı bireyden oluşan iki kontrol grubu çalışmaya dahil edildi. Tükrük ve tiroid bezlerinin fonksiyonu, KTBS ve tiroid fonksiyon ile tiroid antikorlarını içeren laboratuvar testleriyle analiz edildi. Yüz elli MBq Tc-99m perteknetatın intravenöz verilmesinden sonra, dinamik çalışma 25 dakika süreyle gerçekleştirildi. Tükrük bezi sekresyonu, 15. dakikada da oral limon suyu ile uyarıldı. Dinamik çalışmanın sonunda, aynı projeksiyonda statik bir görüntü alındı. Her bir parotis ve submandibuler bezin 12-14 dk tutulum oranları (%UR) ve uyarılmış ekskresyon fraksiyonu (%EF) TBS’den otomatik olarak hesaplandı. Tiroid bezinin tutulum oranı (TUR) statik görüntüden Bulgular: IFN-β1a ile tedavi edilen ve edilmeyen tüm MS hastaları ile sağlıklı bireyler ötiroid idi. Anti-tiroid peroksidaz antikoru (antiTPO), IFN-β1a ile tedavi edilen 15 MS hastasının 4’ünde (%26,6) tespit edildi. IFN-β1a ile tedavi edilen ve edilmeyen tüm MS hastaları ile sağlıklı kontroller arasında UR, EF ve TUR değerlerinde anlamlı fark yoktu (p>0,05). IFN-β1a ile tedavi edilen MS hastalarında TUR değeri, her iki kontrol grubundan düşük olmasına rağmen, fark istatistiksel olarak anlamlı değildi (p>0,05). Sonuç: IFN-β1a tedavisinin, MS hastalarında KTBS ile tiroid ve tükrük bezi fonksiyonları üzerinde etkisi olmadığı gösterilmiştir. Tiroid ve tükrük bezi fonksiyonlarının tedavi edilmemiş MS hastalarında değişmeden kaldığı da bulunmuştur. hesaplandı.

🔖

Cite This Article

ERHAMAMCI, S., HORASANLI, B., AKTAŞ, A. (2014). Multipl Skleroz Hastalarında Interferon-Beta1a Tedavisinin Tiroid ve Tükrük Bezi Fonksiyonları Üzerindeki Etkisinin Kantitatif Tükrük Bezi Sintigrafisi ile Değerlendirilmesi. Molecular Imaging and Radionuclide Therapy, Cilt: 23 - Sayı: 2, 43–47. https://ajindex.com/articles/295161

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Rotondi M, Oliviero A, Profice P, Mone CM, Biondi B, Del Buono A, Mazziotti G, Sinisi AM, Bellastella A, Carella C. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest 1998;21:748-752
  2. Caraccio N, Dardano A, Manfredonia F, Manca L, Pasquali L, Iudice A, Murri L, Ferrannini E, Monzani F. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005;90:4133-4137
  3. Koh L, Greenspan F, Yeo P. Interferon-induced thy¬roid dysfunction: three clinical presentations and review of the literature. Thyroid 1997;7:891-896
  4. Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004;3:199-210
  5. Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol 1997;54:1169-1190
  6. Monzani F, Caraccio N, Meucci G, Lombardo F, Moscato G, Casolaro A, Ferdeghini M, Murri L, Ferrannini E. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 1999;141:325-331
  7. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montarani E, Zaffaroni M; Betaferon Safety Trial Study Group. Thyroid function and autoimmunity during interferon-b 1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001;86:3525-3532
  8. Unoki H, Moriyama A, Tabaru A, Masumoto A, Otsuki M. Development of Sjögren’s syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C. J Gastroenterol 1996;31:723-727
  9. De Santi L, Costantini MC, Annunziata P. Long time interval between multiple sclerosis onset and occurrence of primary Sjögren’s syndrome in a woman treated with interferon-beta. Acta Neurol Scand 2005;112:194-196
  10. Nandula SR, Dey P, Corbin KL, Nunemaker CS, Bagavant H, Deshmukh US. Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling. J Oral Pathol Med 2013;42:66-72
  11. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren’s syndrome. J Autoimmun 2010;35:225-231
  12. Vinagre F, Santos MJ, Prata A, da Silva JC, Santos AI. Assessment of salivary gland fun